Pan-lysyl oxidase inhibition disrupts fibroinflammatory tumor stroma, rendering cholangiocarcinoma susceptible to chemotherapy.

Autor: Burchard PR; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Ruffolo LI; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Ullman NA; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Dale BS; Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA., Dave YA; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Hilty BK; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Ye J; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Georger M; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Jewell R; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Miller C; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., De Las Casas L; Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA., Jarolimek W; Drug Discovery, Syntara Ltd., Sydney, New South Wales, Australia., Perryman L; Drug Discovery, Syntara Ltd., Sydney, New South Wales, Australia., Byrne MM; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Loria A; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Marin C; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Chávez Villa M; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Yeh JJ; Departments of Surgery and Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina System, Chapel Hill, North Carolina, USA., Belt BA; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Linehan DC; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA.; Department of Surgery, Division of Surgical Oncology, University of Rochester Medical Center, Rochester, New York, USA., Hernandez-Alejandro R; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA.; Division of Solid Organ Transplant Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA.

Publikováno v: Hepatology communications [Hepatol Commun] 2024 Aug 05; Vol. 8 (8). Date of Electronic Publication: 2024 Aug 05 (Print Publication: 2024).

Smad4 restricts injury-provoked biliary proliferation and carcinogenesis.

Autor: Alexander WB; Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA.; Department of Medicine, Hematology/Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA., Wang W; Department of Medicine, Hematology/Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA., Hill MA; Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA.; Department of Medicine, Hematology/Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA., O'Dell MR; Department of Medicine, Hematology/Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA., Ruffolo LI; Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA., Guo B; Department of Medicine, Hematology/Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA., Jackson KM; Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA., Ullman N; Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA., Friedland SC; Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA.; Department of Medicine, Hematology/Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA., McCall MN; Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA.; Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY 14642, USA., Patel A; Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA., Figueroa-Guilliani N; Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA., Georger M; Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA., Belt BA; Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA., Whitney-Miller CL; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA., Linehan DC; Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA., Murphy PJ; Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA., Hezel AF; Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA.; Department of Medicine, Hematology/Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA.

Publikováno v: Disease models & mechanisms [Dis Model Mech] 2024 Jun 01; Vol. 17 (6). Date of Electronic Publication: 2024 Feb 28.

GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity.

Autor: Ruffolo LI; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Jackson KM; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Kuhlers PC; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA., Dale BS; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Figueroa Guilliani NM; Department of Surgery, Providence Portland Medical Center, Portland, Oregon, USA., Ullman NA; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Burchard PR; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Qin SS; Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA., Juviler PG; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Keilson JM; Division of Surgical Oncology, Department of Surgery, Emory University, Atlanta, Georgia, USA., Morrison AB; Lineberger Comprehensive Cancer Center, University of North Carolina System, Chapel Hill, North Carolina, USA., Georger M; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA., Jewell R; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Calvi LM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA., Nywening TM; Division of Surgical Oncology, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA., O'Dell MR; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA., Hezel AF; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA., De Las Casas L; Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA., Lesinski GB; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Yeh JJ; Departments of Surgery and Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina System, Chapel Hill, North Carolina, USA., Hernandez-Alejandro R; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Belt BA; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Linehan DC; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA David_Linehan@URMC.Rochester.edu.

Publikováno v: Gut [Gut] 2022 Jul; Vol. 71 (7), pp. 1386-1398. Date of Electronic Publication: 2021 Aug 19.

Pan-Lysyl Oxidase Inhibition with PXS-5505 Improves Survival and Decreases Activated Fibroblast Density in a Mouse Model of Cholangiocarcinoma

Autor: Burchard, P., Ruffolo, L., Ullman, N., Dave, Y., Georger, M., Jewell, R., Belt, B., Linehan, D., Hernandez-Alejandro, R.

Publikováno v: In HPB 2022 24 Supplement 1:S58-S58

Targeting tumor associated macrophages through blockade of GM-CSF sensitizes cholangiocarcinoma to adaptive immunity

Autor: Ruffolo, L.I., Jackson, K.M., Kuhler, P.C., Figueroa-Guilliani, N.M., Ullman, N.A., Burchard, P.R., Dale, B.S., Qin, S., Millian-Keilson, J., Georger, M., Jewell, R., Nywening, T.M., De Las Casas, L., Lesinski, G.B., Yeh, J., Hernandez-Alejandro, R., Belt, B.A., Linehan, D.C.

Publikováno v: In HPB 2021 23 Supplement 2:S472-S472